Replimune Group (NASDAQ:REPL) Sees Unusually-High Trading Volume

Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 1,465,888 shares traded hands during mid-day trading, an increase of 31% from the previous session's volume of 1,115,638 shares.The stock last traded at $11.46 and had previously closed at $11.90.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Barclays boosted their price objective on shares of Replimune Group from $13.00 to $17.00 and gave the stock an "overweight" rating in a research note on Friday, June 7th. Wedbush restated an "outperform" rating and issued a $16.00 price objective on shares of Replimune Group in a research note on Thursday, June 6th. JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, September 24th. HC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Replimune Group in a report on Monday, September 16th. Finally, Roth Capital raised Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Replimune Group currently has a consensus rating of "Buy" and a consensus target price of $16.80.

Replimune Group Trading Up 3.1 %

The company has a market cap of $838.29 million, a P/E ratio of -3.70 and a beta of 1.22. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average price of $10.40 and a 200-day moving average price of $8.55.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.10. On average, analysts forecast that Replimune Group, Inc. will post -3.11 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares in the company, valued at approximately $1,028,760.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 20.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC grew its holdings in shares of Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock worth $28,062,000 after purchasing an additional 2,656,173 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company's stock valued at $18,874,000 after buying an additional 1,679,553 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company's stock valued at $53,505,000 after buying an additional 699,679 shares in the last quarter. Rafferty Asset Management LLC lifted its holdings in shares of Replimune Group by 148.1% during the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company's stock worth $3,906,000 after acquiring an additional 276,596 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Replimune Group during the 1st quarter worth approximately $1,088,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.